Gardasil HPV 9 Vaccine Available in Canada

Gardasil HPV 9 Vaccine Available in Canada

The 9-valent version of the human papillomavirus (HPV) vaccine Gardasil (Merck & Co.) is now available in Canada. This new vaccine offers protection against five more types of HPV than the older Gardasil vaccine, and “has the potential to help prevent 90% of cervical cancers caused by HPV,” says the manufacturer.

The 9-valent vaccine is already available in the United States and has just been recommended for approval in Europe.

In a statement, Vivien Brown, MD, family doctor and board member of Immunize Canada, said “vaccination remains the best method to prevent HPV infection and to protect yourself from the risk of HPV-related diseases.”

“HPV is the most common sexually transmitted infection in Canada and worldwide,” Dr Brown added. “It is estimated that 75% of sexually active Canadian men and women will have at least one anogenital HPV infection in their lifetime.”

Gardasil 9 is indicated for use in girls and women 9 to 45 years of age for the prevention of cervical, vulvar, vaginal, and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58; precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV types 6 and 11.

Gardasil 9 is also approved for use in boys and men 9 to 26 years of age for the prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58; precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV types 6 and 11.

The vaccine is contraindicated in individuals with hypersensitivity, including after a previous dose of either the new 9-valent or the older 4-valent vaccine.

The safety of the new 9-valent vaccine was evaluated in six clinical studies that included more than 13,000 individuals. According to the manufacturer, those clinical trials yielded the following information on adverse events:

  • The most common (≥10%) local and systemic adverse reactions in females 16 through 26 years of age were injection-site pain (89.9%), injection-site swelling (40.0%), injection-site erythema (34.0%), and headache (14.6%).
  • The most common (≥10%) local and systemic reactions in girls 9 through 15 years of age were injection-site pain (89.3%) injection-site swelling (47.8%), injection-site erythema (34.1%), and headache (11.4%).
  • The most common (≥10%) local and systemic reactions in boys 9 through 15 years of age were injection-site pain (70.2%), injection-site swelling (26.0%), and injection-site erythema (24.2%).

Source: Gardasil HPV 9 Vaccine Launched in Canada

Photo Credit: Shutterstock

No Comments

Post A Comment